Skip to main content
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · IEX Real-Time Price · USD
26.43
+0.09 (0.34%)
May 17, 2024, 4:00 PM EDT - Market closed

Cartesian Therapeutics Revenue

Cartesian Therapeutics had revenue of $25.91M in the twelve months ending March 31, 2024, down -68.68% year-over-year. Revenue in the quarter ending March 31, 2024 was $5.84M, a -1.65% decrease year-over-year. In the year 2023, Cartesian Therapeutics had annual revenue of $26.00M, a decrease of -76.53%.

Revenue (ttm)
$25.91M
Revenue Growth
-68.68%
P/S Ratio
18.16
Revenue / Employee
$700,162
Employees
37
Market Cap
470.35M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202326.00M-84.77M-76.53%
Dec 31, 2022110.78M25.70M30.21%
Dec 31, 202185.08M68.48M412.60%
Dec 31, 202016.60M9.92M148.57%
Dec 31, 20196.68M5.77M639.42%
Dec 31, 2018903.00K696.00K336.23%
Dec 31, 2017207.00K-7.88M-97.44%
Dec 31, 20168.08M2.07M34.47%
Dec 31, 20156.01M2.97M97.73%
Dec 31, 20143.04M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
ZimVie 350.20M
Travere Therapeutics 183.23M
Talkspace 162.13M
UroGen Pharma 84.30M
Editas Medicine 69.41M
Verve Therapeutics 16.05M
TScan Therapeutics 14.81M
Fulcrum Therapeutics 2.51M
Revenue Rankings

RNAC News

More News